Conson Pharmaceuticals Enters China Top 100 Pharma List on July 12, Sales Hit 3.42B Yuan

According to the China Pharmaceutical Industry Information Center, Conson Pharmaceuticals (01681) entered China's top 100 pharmaceutical industrial enterprises list for the first time on July 12 and was rated as a company with investment potential in the sector.

The company reported full-year sales revenue of approximately 3.42 billion yuan (RMB) in 2025, up 15.2% year-over-year, with market value breaking the 10 billion yuan mark. The company, listed on the Hong Kong Stock Exchange's main board in 2013, specializes in pharmaceutical R&D, manufacturing, and marketing operations.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments